Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab.
| Autor: | Strava Corrêa, Tatiana1 tatiana.scorrea@hsl.org.br, Ramos Matos, Gustavo Duarte2, Segura, Marcos3, dos Anjos, Carlos Henrique1 |
|---|---|
| Zdroj: | Case Reports in Oncology. May-Aug2018, Vol. 11 Issue 2, p252-257. 6p. |
| Databáze: | Academic Search Ultimate |
| Externí odkaz: |
|